Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these

Insiders' dealing


Report of transactions with shares and related securities of NeuroSearch by
persons discharging managerial responsibilities and persons/companies closely
associated with these 

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public, transactions with shares and related
securities of NeuroSearch A/S by persons discharging managerial
responsibilities and persons/companies closely associated with these. 


Name: Jette Møllmann
Reason: Vice President, Director of Legal Affairs
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 12 March 2008
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 1,545
Market value (DKK): 435,690

Name: Daniel Brunicardi Timmermann
Reason: Vice President, Director of Ion Channel Therapeutics
Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666
Transaction: Sale of shares
Trading date: 12 March 2008
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 1,545
Market value (DKK): 435,690



Contact person: 
Anita Milland, Vice President, CFO, telephone: +45 2016 3432



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with
Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as
well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in
collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with
GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a
broad portfolio of preclinical drug candidates and holds equity interests in
several biotech companies.